In non‐alcoholic fatty liver disease, USP14 stabilises HSP90AA1 through deubiquitination, leading to increased levels of CYP2E1 and further exacerbating disease progression [32]. Here, USP14 is linked to metabolic dysfunction-associated steatotic liver disease.